BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi MS, Yoo BC. Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver 2010;4:15-24. [PMID: 20479908 DOI: 10.5009/gnl.2010.4.1.15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen NH, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol. 2015;30:43-50. [PMID: 25168842 DOI: 10.1111/jgh.12728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753 [PMID: 25759545 DOI: 10.3748/wjg.v21.i9.2746] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
3 Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980-988. [PMID: 24368224 DOI: 10.1053/j.gastro.2013.12.028] [Cited by in Crossref: 118] [Cited by in F6Publishing: 108] [Article Influence: 13.1] [Reference Citation Analysis]
4 Choi MS, Sinn DH, Kim SA, Lee YS, Choi W, Paik SW. The clinical and laboratory characteristics of patients with chronic hepatitis B using current or past antiviral therapy in Korea: a multi-center, nation-wide, cross-sectional epidemiologic study. Gut Liver 2012;6:241-8. [PMID: 22570755 DOI: 10.5009/gnl.2012.6.2.241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer. 2011;11:398. [PMID: 21933446 DOI: 10.1186/1471-2407-11-398] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
6 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Kuipery A, Gehring AJ, Isogawa M. Mechanisms of HBV immune evasion. Antiviral Res. 2020;179:104816. [PMID: 32387476 DOI: 10.1016/j.antiviral.2020.104816] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
8 Park HN, Sinn DH, Gwak GY, Kim JE, Rhee SY, Eo SJ, Kim YJ, Choi MS, Lee JH, Koh KC. Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. Liver Int. 2012;32:937-944. [PMID: 22260521 DOI: 10.1111/j.1478-3231.2011.02749.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
9 Fuentes Olmo J, Uribarrena Amézaga R. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?]. Gastroenterol Hepatol 2011;34:492-503. [PMID: 21550145 DOI: 10.1016/j.gastrohep.2011.02.009] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434-442. [PMID: 23939953 DOI: 10.1002/hep.26686] [Cited by in Crossref: 164] [Cited by in F6Publishing: 152] [Article Influence: 20.5] [Reference Citation Analysis]
11 Zhang S, Ristau JT, Trinh HN, Garcia RT, Nguyen HA, Nguyen MH. Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study. Dig Dis Sci 2012;57:1373-83. [PMID: 22466077 DOI: 10.1007/s10620-012-2137-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
12 Kim KH, Sinn DH, Yun WK, Cho HC, Lee YY, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. Defining virologic relapse in chronic hepatitis B. Dig Dis Sci 2011;56:2432-8. [PMID: 21318588 DOI: 10.1007/s10620-011-1597-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Nguyen NH, Nguyen V, Trinh HN, Lin B, Nguyen MH. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol 2013;11:565-71. [PMID: 23333662 DOI: 10.1016/j.cgh.2012.12.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]